Yandong Wang, Chief Pharmacist, Director of the Department of Pharmacy at Zhongshan Ophthalmic Center Sun Yat-sen University, Doctor of Biology and Medicine, Master Tutor, Outstanding Young Medical Talents of Guangdong Province, Director of Guangdong Ophthalmic Drug Development and Evaluation Engineering Technology Research Center. He has been applied himself to the creation and development of ophthalmic drugs.He has led more than 30 eye drops pre-clinical studies. He has obtained three first-in-class innovative drugs, two class 2 new drugs and one class 3 new drug clinical approvals and 14 drug production license. He has been granted 35 invention patents, published more than 14 SCI papers and compiled 6 monographs. He has undertaken more than 10 provincial and ministerial-level research projects and transformed 8 technology achievements. ZOC2017217 eye drops was the first-in-class innovative cataract drug，has obtained more than 20 national compound invention patents and clinical approval. It has completed Phase I and Phase II clinical trials with positive results and entered Phase III clinical trials. It has achieved a major breakthrough in cataract treatment and technology achievement transformation with 1.38 billion yuan. ZOC2019619 eye drops was the first-in-class innovative glaucoma drug，has obtained clinical approval and entered Phase II clinical trials. It has and technology achievement transformation with 275 million yuan. It has solved glaucoma drugs bottlenecks in China.
Yandong Wang, Chief Pharmacist, Director of the Department of Pharmacy at Zhongshan Ophthalmic Center Sun Yat-sen University, Doctor of Biology and Medicine, Master Tutor, Outstanding Young Medical Talents of Guangdong Province, Director of Guangdong Ophthalmic Drug Development and Evaluation Engineering Technology Research Center. He has been applied himself to the creation and development of ophthalmic drugs.He has led more than 30 eye drops pre-clinical studies. He has obtained three first-in-class innovative drugs, two class 2 new drugs and one class 3 new drug clinical approvals and 14 drug production license. He has been granted 35 invention patents, published more than 14 SCI papers and compiled 6 monographs. He has undertaken more than 10 provincial and ministerial-level research projects and transformed 8 technology achievements. ZOC2017217 eye drops was the first-in-class innovative cataract drug，has obtained more than 20 national compound invention patents and clinical approval. It has completed Phase I and Phase II clinical trials with positive results and entered Phase III clinical trials. It has achieved a major breakthrough in cataract treatment and technology achievement transformation with 1.38 billion yuan. ZOC2019619 eye drops was the first-in-class innovative glaucoma drug，has obtained clinical approval and entered Phase II clinical trials. It has and technology achievement transformation with 275 million yuan. It has solved glaucoma drugs bottlenecks in China.
